Pharmatest to present new data on prostate cancer at Barcelona Symposium

Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services will present novel data on prostate cancer therapy when it attends the upcoming EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics.

Jussi Halleen, CEO of Pharmatest, will lead the company’s team at the 26th EORTC-NCI-AACR Symposium in Barcelona, opening on November 18.

During a symposium, Pharmatest will share novel data gathered with Bayer Healthcare about radium-223 dichloride efficacy in treating prostate cancer in mouse models.

Prostate bone metastasis

The Pharmatest research team, headed by Mari Suominen, will present a poster (P057) entitled: “Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis”.

Pharmatest is accepting emailed requests and invitations for face-to-face meetings at the Barcelona Symposium at [email protected]

About Pharmatest Services

Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models.

Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

The CRO has supported close to 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

About EORTC-NCI-AACR Symposium

The 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place in Barcelona, 18-21 November 2014.

Jointly hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.

The event is expected to attract around 2,000 academics, scientists and pharmaceutical industry representatives from around the globe to the Centre de Convencions Internacional Barcelona (CCIB).

The conference will be combined with an industry exhibition featuring more than 30 research-based organizations and companies.

The event is administered by European Cancer Organization (ECCO), which says the symposium is unique in providing a scientific forum for developing drugs for the future.

The 2014 event aims to build on the success of the 2013 symposium in Boston, which was widely praised for the quality of its programme, inspirational contributions and exclusive insights.

More information available at http://www.ecco-org.eu/Events/EORTC_NCI_AACR_2014